- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1747 |
Product Name |
ADT1747-Human Anti-EGFRxMET Bispecific Antibody |
Isotype |
Human IgG1-kappa |
Clonity |
Monoclonal |
|
Alternate Names Human Anti-EGFR mAb, Anti-EGFR Monoclonal Antibody, EGFR recombinant antibody, Anti-EGFR Bispecific Antibody, Human Anti-MET mAb, MET recombinant antibody, Anti-MET Monoclonal Antibody, Anti-MET Bispecific Antibody |
|
Official Symbol |
EGFRxMET |
Target 1 |
EGFR |
Gene ID 1 |
1956 |
Target 2 |
MET |
Gene ID 2 |
4233 |
Species |
Human |
Drug Name |
Amivantamab |
Endotoxin |
<1EU/mg. Determined by the LAL method. |
Sterility |
0.2 μM filtered. |
Expression Host |
CHO Cells |
CAS Number |
2171511-58-1 |
Molecular Weight |
148 KDa |
Product Description |
Amivantamab is an EGF and MET receptor targeted antibody indicated in the treatment of non-small cell lung cancer with an EGFR 20 exon insertion mutation. |
Mechanism of Action |
Amivantamab targets both EGFR and MET, preventing ligands from binding to the receptors, blocking signalling, marking the cancerous cells for antibody-dependant cellular cytotoxicity by natural killer cells, and allowing macrophages to perform trogocytosis.
|
Metabolism |
Antibodies are expected to be metabolized to oligopeptides and amino acids. |
Size |
1mg,5mg,50mg,100mg |
Research Area |
Cancer |
Application |
FuncS |
Purity |
>90% |
Concentration |
Batch dependent |
Buffer |
Supplied in PBS, pH 7.4,Contains no stabilizers or preservatives |
Recommended Dilution Buffer |
ABDB-1002 or PBS, pH 7.4, Contains no stabilizers or preservatives. |
Storage |
2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for one-year storage. |
Shipping Condition |
Shipped on ice packs. |
Protocol Information |
Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose-response or titration experiment. |
Note |
For Research Use Only! |
|
Reference 1. Neijssen J, Cardoso RMF, Chevalier KM, Wiegman L, Valerius T, Anderson GM, Moores SL, Schuurman J, Parren PWHI, Strohl WR, Chiu ML: Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. J Biol Chem. 2021 Apr 8:100641. doi: 10.1016/j.jbc.2021.100641.
2. Jarantow SW, Bushey BS, Pardinas JR, Boakye K, Lacy ER, Sanders R, Sepulveda MA, Moores SL, Chiu ML: Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor x c-MET Bispecific Antibody. J Biol Chem. 2015 Oct 9;290(41):24689-704. doi: 10.1074/jbc.M115.651653. Epub 2015 Aug 10.
|
FAQ
-
+ -
Why target EGFR and MET?
EGFR drives tumor proliferation, while MET activation causes resistance to EGFR inhibitors. Dual targeting addresses both pathways.
-
+ -
How can I obtain COA of the reagent that I received?
Please contact us via email info@alphalifetech.com for detailed information about the product.
-
+ -
What are bispecific antibodies (BsAbs)?
A bispecific antibody (BsAb) is an engineered antibody capable of binding two distinct antigens or epitopes simultaneously, enabling novel therapeutic mechanisms not achievable with monoclonal antibodies. -
+ -
How do bispecific antibodies differ from monoclonal antibodies?
Unlike monoclonal antibodies (targeting one antigen), BsAbs engage two targets, facilitating dual-pathway inhibition, immune cell recruitment, or bridging cells (e.g., T-cells and tumor cells).